Volpara inks deal with Microsoft, how will its shares react?

The shares were performing in line with the ASX 200 healthcare index (XHJ), which was down 0.977% at the same time. In the last five trading sessions, the shares tumbled 23%, and in one month, shares dropped 36%. On a year-to-date basis, the share price sank by 57%.

Microsoft has a great advantage in the field of Artificial Intelligence and computing services. The product to be developed under the collaboration will use AI and mammograms and capitalise upon the recent BAC patent granted to Volpara. Microsoft’s machine learning and AI specialists would support improving the BACs model along with data processing.

Microsoft and Volpara, together, will be working towards bettering women’s health through science and innovation, VHT release stated. The BACs product would help radiologists identify the need to take steps to prevent heart disease. It would work as a cardiac decision-support tool and mark the entry of Volpara into a new area of care.